Company Profile

GLSynthesis Inc (AKA: The Fluorosome Company)
Profile last edited on: 10/31/2023      CAGE: 3R5C7      UEI: UKS9MJNSGBE7

Business Identifier: Custom organic synthesis, drug and chemical product R&D, pharmacology, international chemical production and sales
Year Founded
1996
First Award
1998
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

298 Highland Street
Worcester, MA 01602
   (774) 253-0904
   support@glsynthesis.com
   www.glsynthesis.com
Location: Single
Congr. District: 02
County: Worcester

Public Profile

GLSynthesis performs laboratory scale (custom) organic synthesis for major US and international pharmaceutical companies, startup drug discovery and "virtual" companies, biotechnology companies, and academic and research institutions. The company carries out drug discovery and development research, including synthesis, pharmacokinetic studies and pharmacological testing of drug candidates, through corporate contracts and small business (NIH) grants. The firm is developing the Fluorosome® Technique for passive and active drug absorption studies, and is actively marketing the reagents and equipment. The firm manufactures specialty organic chemicals and pharmaceutical intermediates and supplies these products to customers worldwide. With its expanded operations in China, GLSynthesis provides customers with a full range of chemical manufacturing services, from small scale custom synthesis, to FTE-based contract synthesis, to pilot scale and commercial scale manufacturing. The company's laboratories are in the Massachusetts Biotechnology Research Park, Worcester, MA and its production facilities are in China.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 2 NIH $1,638,274
Project Title: Production and Inhibition Assay for Bile Salt Export Protein
2017 2 NIH $1,512,842
Project Title: Development of a Fluorescence Liposomal ABCG2 Multidrug Transporter Assay
2015 2 NIH $5,204,906
Project Title: Novel Antithrombotic Diadenosine Tetraphosphate Analogs
2015 1 NIH $320,466
Project Title: A Novel Drug Detection Assay Using Fluorescent Biosensor Technology
2013 1 NIH $237,357
Project Title: A Soft Topical Antiandrogenic Drug

Key People / Management

  Jan L Chen -- CEO

  George E Wright -- President

  Praveen Bansal

  Vincent B Ciofalo

  Sofya Dvoskin

  Karsten A Holm

  Andrew T Maioli

  Donald L Melchior

  Paul M Tarantino

  George E Wright

  Wei-Chu Xu

  Ivan B Yanachkov

Company News

There are no news available.